AVXL down near recent lows today.......another good post from IHUB,
Fletch
falconer66a Tuesday, 01/16/18 12:21:25 PM
Re: bennyboy1 post# 137472
Post # of 137565
Just An Iceberg?
Much has been made of Dr. Missling’s “tip of the iceberg” comment; implying that there’s a lot more to the Anavex story than is currently known or announced.
For those not interested in informed conjecture, click away right now. Stay firmly with what you know you know. Period.
Here’s what I know, having useful levels of education and understanding of biochemistry, cytology, genetics, molecular metabolism, and all the other mechanisms and processes that the Anavex drugs affect, control, and restore.
The Anavex molecules, both in clinical trials and back in the pipeline, have no comparison to the many dozens of other drugs on pharmacy shelves or in drug company research labs. They are entirely different; an entirely new class or category of drugs that have the potential of transforming 21st-century medicine more than antibiotics did in the 20th century.
This is lost on most investors, institutional or retail; where the Anavex drugs are regarded as merely more of the same. Some slightly new, or slight re-configurations of existing drugs, reworked and tossed at some big diseases. Like the vast majority of the others, the Anavex drugs will fail, too. Those folks assess the Anavex story in absolute relation to the many dozens of previous drug development failures. In their wisdom, they know that only a fraction of new drugs attain Phase 3 outcomes that allow clinical usage. Never bet on any drug that hasn’t even had a Phase 3 trial yet.
I’ll state this in quotations, to give a generalized notion of how different Anavex sigma-1 receptor agonists are: “They fix everything.”
Do they? Well, probably not. But on the other hand, as determined in the Australian trial, they do fix a number of un-targeted conditions. The drug did stop or reverse progression of Alzheimer’s dementia, the targeted outcome. But in addition, it also treated the insomnia common to the Alzheimer’s condition. And today, we learn it also treated hypertension. Three for the price of the expected one.
More importantly, how could this be? How could one molecule have at least three very unconnected, positive outcomes? Because of its unique mechanism of action, it’s ability to “fix” things “broken” in the cell.
In all of these, those with Alzheimer’s, Parkinson’s, multiple sclerosis, insomnia, and hypertension did not have any of these conditions in earlier periods in their lives. All of these occurred with age, as cellular processes began to break down. Anavex 2-73, by its allowance of the endoplasmic reticula to once again fold and make functioning enzymes, restores a youthful cellular health.
Therein is the unseen ice. The fact is this. Virtually all chemical reactions, therefore, all cellular processes, are controlled by well-formed enzymes. If improperly folded, enzymes fail to moderate essential cellular chemistries. Those bent molecules are pathogenic, causing or allowing the cell and associated organs to malfunction; become diseased.
I’ve conjectured before that a lot of back of the lab work has been done on numerous diseased rats or mice, being treated with any of the several Anavex pipeline drugs. There is a high chance that they really do “fix everything,” restore normalized cell function. Their unique mechanisms of reaction cause this. The Anavex pipeline page tells of applications for depression, stroke, pains, and a cancer. All of those are entirely different from the targeted CNS diseases, insomnia, and now, hypertension. Can one new class or category of drugs have these multiple or diverse applications? Yes — and probably many more.
Let’s watch for new Anavex announcements involving any number of other diseases and conditions. The Anavex chunk of ice may not be just an iceberg; rather, a continental glacier.
Fletch
falconer66a Tuesday, 01/16/18 12:21:25 PM
Re: bennyboy1 post# 137472
Post # of 137565
Just An Iceberg?
Much has been made of Dr. Missling’s “tip of the iceberg” comment; implying that there’s a lot more to the Anavex story than is currently known or announced.
For those not interested in informed conjecture, click away right now. Stay firmly with what you know you know. Period.
Here’s what I know, having useful levels of education and understanding of biochemistry, cytology, genetics, molecular metabolism, and all the other mechanisms and processes that the Anavex drugs affect, control, and restore.
The Anavex molecules, both in clinical trials and back in the pipeline, have no comparison to the many dozens of other drugs on pharmacy shelves or in drug company research labs. They are entirely different; an entirely new class or category of drugs that have the potential of transforming 21st-century medicine more than antibiotics did in the 20th century.
This is lost on most investors, institutional or retail; where the Anavex drugs are regarded as merely more of the same. Some slightly new, or slight re-configurations of existing drugs, reworked and tossed at some big diseases. Like the vast majority of the others, the Anavex drugs will fail, too. Those folks assess the Anavex story in absolute relation to the many dozens of previous drug development failures. In their wisdom, they know that only a fraction of new drugs attain Phase 3 outcomes that allow clinical usage. Never bet on any drug that hasn’t even had a Phase 3 trial yet.
I’ll state this in quotations, to give a generalized notion of how different Anavex sigma-1 receptor agonists are: “They fix everything.”
Do they? Well, probably not. But on the other hand, as determined in the Australian trial, they do fix a number of un-targeted conditions. The drug did stop or reverse progression of Alzheimer’s dementia, the targeted outcome. But in addition, it also treated the insomnia common to the Alzheimer’s condition. And today, we learn it also treated hypertension. Three for the price of the expected one.
More importantly, how could this be? How could one molecule have at least three very unconnected, positive outcomes? Because of its unique mechanism of action, it’s ability to “fix” things “broken” in the cell.
In all of these, those with Alzheimer’s, Parkinson’s, multiple sclerosis, insomnia, and hypertension did not have any of these conditions in earlier periods in their lives. All of these occurred with age, as cellular processes began to break down. Anavex 2-73, by its allowance of the endoplasmic reticula to once again fold and make functioning enzymes, restores a youthful cellular health.
Therein is the unseen ice. The fact is this. Virtually all chemical reactions, therefore, all cellular processes, are controlled by well-formed enzymes. If improperly folded, enzymes fail to moderate essential cellular chemistries. Those bent molecules are pathogenic, causing or allowing the cell and associated organs to malfunction; become diseased.
I’ve conjectured before that a lot of back of the lab work has been done on numerous diseased rats or mice, being treated with any of the several Anavex pipeline drugs. There is a high chance that they really do “fix everything,” restore normalized cell function. Their unique mechanisms of reaction cause this. The Anavex pipeline page tells of applications for depression, stroke, pains, and a cancer. All of those are entirely different from the targeted CNS diseases, insomnia, and now, hypertension. Can one new class or category of drugs have these multiple or diverse applications? Yes — and probably many more.
Let’s watch for new Anavex announcements involving any number of other diseases and conditions. The Anavex chunk of ice may not be just an iceberg; rather, a continental glacier.
1
